18-hydroxy-19-norcorticosterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

18-hydroxy-19-norcorticosterone (18-OH-19-norcorticosterone) is a **synthetic steroid** that is structurally similar to the natural hormone **corticosterone**.

Here's why it's important in research:

* **Selective Mineralocorticoid Receptor (MR) Agonist:** 18-OH-19-norcorticosterone is a potent and selective agonist of the MR, meaning it binds to and activates the MR. This makes it a valuable tool for studying the role of the MR in various physiological processes.
* **Potential Therapeutic Applications:** Due to its selectivity for MR, 18-OH-19-norcorticosterone has potential therapeutic applications in conditions like:
* **Heart failure:** MR activation plays a role in heart failure progression. 18-OH-19-norcorticosterone might be useful in managing heart failure by targeting specific MR-mediated pathways.
* **Kidney disease:** MR activation can contribute to salt and water retention in kidney disease. Selective MR agonists like 18-OH-19-norcorticosterone could potentially be used to modulate these effects.
* **Neurological disorders:** MR signaling is involved in various brain functions. 18-OH-19-norcorticosterone might be explored as a potential treatment for conditions like Alzheimer's disease and anxiety.
* **Understanding MR Pharmacology:** 18-OH-19-norcorticosterone is a valuable tool for studying the pharmacology of the MR. Its selectivity allows researchers to differentiate the effects of MR activation from those of other steroid receptors like the glucocorticoid receptor (GR).

**Research using 18-OH-19-norcorticosterone is ongoing to better understand its potential therapeutic benefits and to refine its use in research settings.**

It's important to note that 18-OH-19-norcorticosterone is still under investigation, and its clinical applications are not yet fully established. More research is needed to determine its safety and efficacy in humans.

18-hydroxy-19-norcorticosterone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	130685
MeSH ID	M0146210

Synonyms (7)

Synonym
111594-84-4
18-hydroxy-19-norcorticosterone
19-norpregn-4-ene-3,20-dione, 11,18,21-trihydroxy-, (11beta)-
18-oh-19-nc
(8s,9s,10r,11s,13r,14s,17s)-11-hydroxy-17-(2-hydroxyacetyl)-13-(hydroxymethyl)-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one
DTXSID40912234
11,18,21-trihydroxy-19-norpregn-4-ene-3,20-dione

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (33.33)	18.7374
1990's	6 (66.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.31 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.62 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
corticosterone [no description available]	2.88	4	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
aldosterone [no description available]	3.36	7	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
pregnenolone [no description available]	1.98	1	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
18-hydroxycorticosterone [no description available]	8.58	9	11beta-hydroxy steroid; 18-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo steroid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
19-noraldosterone [no description available]	2.9	4	21-hydroxy steroid
18,19-dihydroxycorticosterone 18,19-dihydroxycorticosterone: structure given in first source	3.08	5
19-norcorticosterone [no description available]	6.96	1
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	1.99	1	amino acid zwitterion; angiotensin II	human metabolite
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	1.97	1	vasopressin	cardiovascular drug; hematologic agent; mitogen
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(o- methyl-l-tyrosine)-8-l-arginine- vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-: highly potent antagonist of vasopressor response to arginine-vasopressin; structure in first source	1.97	1

Condition	Relationship Strength	Studies
Adenoma, Basal Cell [description not available]	2.38	2
Adrenal Cancer [description not available]	2.38	2
Aldosteronism [description not available]	2.38	2
Adenoma A benign epithelial tumor with a glandular organization.	2.38	2
Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.	7.38	2
Blood Pressure, High [description not available]	2.66	3
Cirrhosis, Liver [description not available]	1.97	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.66	3
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	1.97	1
Cushing's Syndrome [description not available]	1.97	1
Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.	1.97	1

chemdatabank.com